| Old Articles: <Older 53511-53520 Newer> |
|---|
 |
The Motley Fool
November 15, 2011
Brian Orelli |
Good Data, Big Drug Market, but Still Risky Eli Lilly's evacetrapib is behind Roche and Merck.   |
The Motley Fool
November 15, 2011
Anders Bylund |
Motricity Is Late to the Smartphone Party There are enough red flags here to equip Seville's matadors for decades to come. |
The Motley Fool
November 15, 2011
Brian Stoffel |
Our Analysts Are Gobbling Up These Shares Motley Fool analysts are buying these five stocks right now: ArcelorMittal... Infinera... Devon Energy... Ecolab... Heineken... |
The Motley Fool
November 15, 2011
Esterhuizen & Lipman |
Hedging Europe's Debt Crisis: Here Are 10 Debt-Free, Undervalued Stocks These ten companies have no debt, and they appear to be undervalued relative to their cash flows -- should any of these names be on your radar? |
The Motley Fool
November 15, 2011
Rick Aristotle Munarriz |
Give Sirius XM Some Time Earnings will continue to ramp up at Sirius XM. |
The Motley Fool
November 15, 2011
Vibhuti Shah |
An Opportunity Is Brewing for This Stock With shares of the specialty coffee company Green Mountain falling recently, has the company turned bitter for investors? |
The Motley Fool
November 15, 2011
Ilan Moscovitz |
5 High-Yield Stocks You May Be Ignoring It's time to get greedy. |
The Motley Fool
November 15, 2011
Shubh Datta |
AIG and Losses Go Hand in Hand AIG posts biggest quarterly loss since 2009. |
The Motley Fool
November 15, 2011
Alyce Lomax |
Starbucks' Darwinian Twist The coffee giant's eyeing a brand-new area for growth. |
The Motley Fool
November 15, 2011
Selena Maranjian |
Make Money in Biotech and Genome Stocks the Easy Way If you expect biotech firms and companies specializing in genomics to thrive as advances in health care and medicine continue, the PowerShares Dynamic Biotech & Genome ETF could save you a lot of trouble. |
| <Older 53511-53520 Newer> Return to current articles. |
